When are men eligible for testosterone therapy?

When Men Are Eligible for Testosterone Therapy

Men are eligible for testosterone therapy when they have both consistently low testosterone levels (below 300 ng/dL on two separate early morning measurements) AND symptoms or signs of testosterone deficiency, or when they have established organic hypogonadism from disorders of the hypothalamus, pituitary, or testes. 1, 2

FDA-Approved Indications

Testosterone is FDA-approved for replacement therapy in men with:2

• Primary hypogonadism (testicular failure from cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy)
• Hypogonadotropic hypogonadism (idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation)

Diagnostic Criteria for Testosterone Deficiency

Laboratory Requirements

The American Urological Association establishes clear thresholds:1

• Total testosterone below 300 ng/dL serves as the diagnostic cut-off
• Two separate measurements required, both obtained as fasting early morning samples
• Use the same laboratory and methodology for consistency

Clinical Requirements

Diagnosis requires BOTH low testosterone AND clinical manifestations:1

Key symptoms to assess:

• Reduced sexual desire and erectile dysfunction
• Decreased energy, endurance, and physical performance
• Fatigue and reduced motivation
• Depression, poor concentration, and impaired memory
• Infertility

Physical examination findings:

• Body habitus and virilization status (body hair patterns in androgen-dependent areas)
• Gynecomastia
• Testicular size, consistency, and presence of masses
• Body mass index or waist circumference

High-Risk Populations Warranting Screening

Even without symptoms, measure testosterone in men with:1

• Unexplained anemia
• Bone density loss
• Diabetes
• Exposure to chemotherapy or testicular radiation
• HIV/AIDS
• Chronic narcotic use
• Male infertility
• Pituitary dysfunction
• Chronic corticosteroid use

Important Distinctions: Organic vs. Functional Hypogonadism

The evidence distinguishes between two populations:1

Organic/Classical Hypogonadism: Men with established hypothalamic-pituitary-testicular axis disease (Klinefelter syndrome, orchitis, testicular trauma/radiation, pituitary tumors) are unequivocally eligible for testosterone therapy as standard care.1, 2

Functional/Late-Onset Hypogonadism: Older men with low testosterone from aging, obesity, or comorbidities represent a more nuanced scenario. The American College of Physicians found that testosterone therapy in these men provides only small improvements in sexual function and quality of life, with little benefit for physical function, energy, or cognition.1 Long-term safety remains unknown, and approximately 25% of men currently receiving testosterone do not meet diagnostic criteria.1

Absolute Contraindications

Do NOT initiate testosterone therapy in men with:3

• Breast or prostate cancer
• Palpable prostate nodule or induration
• PSA >4 ng/dL (or >3 ng/dL in high-risk men without urological evaluation)
• Elevated hematocrit
• Untreated severe obstructive sleep apnea
• Severe lower urinary tract symptoms
• Uncontrolled heart failure
• Myocardial infarction or stroke within 6 months
• Thrombophilia
• Men planning fertility in the near term

Critical Pitfalls to Avoid

Common errors in practice:1

• Approximately 25% of men receiving testosterone do not meet diagnostic criteria
• Nearly half of treated men never have follow-up testosterone levels checked
• 20% of men starting therapy had baseline testosterone above 300 ng/dL
• Validated questionnaires should NOT be used to determine eligibility—they cannot replace proper clinical and laboratory evaluation1

Pre-Treatment Requirements

Before initiating therapy:3

• PSA and digital rectal examination in men >40 years to exclude occult prostate cancer
• Baseline hematocrit measurement
• Document both low testosterone levels AND clinical symptoms/signs
• Exclude organic causes requiring specific management

The evidence strongly supports testosterone therapy for men with organic hypogonadism, while emphasizing more cautious, symptom-driven approaches for functional hypogonadism with explicit discussion of uncertain long-term benefits and risks.1, 4, 3